Max pain is the price where the total value of all open calls and puts would be lowest at expiration, so option buyers as a group would lose the most. Some traders watch it as a level the stock may drift toward near expiration, because option sellers, often market makers, hedge their positions in ways that can pull the price toward heavily traded strikes. It is a theory, not a guarantee.

As of the Nov 4, 2026 close, max pain for Repligen options about one week from expiration was $170.92. The chart above shows the exact max pain for each expiration date.

Repligen closed above its near-term max pain on 14 of the last 20 trading days. On Nov 4, 2026 it closed at $178.30, 4.3% above max pain of $170.92.

Over the last 20 trading days, near-term max pain for Repligen ranged from $156.40 to $185.13. It went from $185.13 on Oct 8, 2026 to $170.92 on Nov 4, 2026. See the RGEN max pain history for a longer view.

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies.